Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21660 (2021).

Article  PubMed  Google Scholar 

Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. WHO classification of tumours of the digestive system: WHO Classification of Tumours 4th edn. Vol. 3 (IARC, 2010).

Bass, A. J. et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).

Google Scholar 

Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456 (2015).

CAS  PubMed  Google Scholar 

Thun, M. J., Wild, C. P. & Colditz, G. in Schottenfeld Fraumeni Cancer Epidemiology and Prevention 4th edn (eds Thun, M. J., Linet, M. S., Cerhan, J. R., Haiman, C. A. & Schottenfeld, D.) 1193–1204 (Oxford Univ. Press, 2017).

The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).

PubMed Central  Google Scholar 

Lordick, F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. https://doi.org/10.1016/J.ANNONC.2022.07.004 (2022).

Article  PubMed  Google Scholar 

American Cancer Society. Cancer facts & figures 2021 (American Cancer Society, 2021).

Davidson, M. et al. Survival in advanced esophagogastric adenocarcinoma improves with use of multiple lines of therapy: results from an analysis of more than 500 patients. Clin Colorectal Cancer 17, 223–230 (2018).

PubMed  Google Scholar 

Fanotto, V. et al. Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist 22, 1463–1469 (2017).

PubMed  PubMed Central  Google Scholar 

Cafferkey, C. et al. Survival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: results from an analysis of over 500 patients (pts) [abstract 642P]. Ann. Oncol. 28 (Suppl. 5), v219 (2017).

Google Scholar 

Hess, L. M. et al. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer 19, 607–615 (2016).

CAS  PubMed  Google Scholar 

Deng, N. et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673–684 (2012).

CAS  PubMed  Google Scholar 

Dulak, A. M. et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383–4393 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Sohn, B. H. et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project. Clin. Cancer Res. 23, 4441–4449 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49–58 (2018).

CAS  PubMed  Google Scholar 

Suh, Y. S. et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas. Ann. Surg. 275, 706–717 (2022).

PubMed  Google Scholar 

Tabernero, J. et al. End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC) [abstract 1423MO]. Ann. Oncol. 31 (Suppl. 4), S900–S901 (2020).

Google Scholar 

Satoh, T. et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J. Clin. Oncol. 32, 2039–2049 (2014).

CAS  PubMed  Google Scholar 

Hecht, J. R. et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC–a randomized phase III trial. J. Clin. Oncol. 34, 443–451 (2016).

CAS  PubMed  Google Scholar 

Thuss-Patience, P. C. et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 18, 640–653 (2017).

CAS  PubMed  Google Scholar 

Waddell, T. et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 481–489 (2013).

CAS  PubMed  PubMed Central  Google Scholar 

Lordick, F. et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 490–499 (2013).

CAS  PubMed  Google Scholar 

Dutton, S. J. et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 15, 894–904 (2014).

CAS  PubMed  Google Scholar 

Catenacci, D. V. T. et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1467–1482 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Shah, M. A. et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric Randomized Clinical Trial. JAMA Oncol. 3, 620–627 (2017).

PubMed  Google Scholar 

Alsina, M., Gullo, I. & Carneiro, F. Intratumoral heterogeneity in gastric cancer: a new challenge to face. Ann. Oncol. 28, 912–913 (2017).

CAS  PubMed  Google Scholar 

Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y. & Shitara, K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat. Rev. Clin. Oncol. 18, 473–487 (2021).

PubMed  Google Scholar 

Pectasides, E. et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 8, 37–48 (2018).

CAS  PubMed  Google Scholar 

Gullo, I., Carneiro, F., Oliveira, C. & Almeida, G. M. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology 85, 50–63 (2018).

PubMed  Google Scholar 

Catenacci, D. V. T. et al. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 11, 308–325 (2021).

CAS  PubMed  Google Scholar 

Nakamura, Y. et al. Emergence of concurrent multiple EGFR mutations and MET amplification in a patient with EGFR-amplified advanced gastric cancer treated with cetuximab. JCO Precis. Oncol. 4, 1407–1413 (2020).

Google Scholar 

Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415–1421 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 323, 1311–1315 (1984).

Google Scholar 

Engstrand, L. & Graham, D. Y. Microbiome and gastric cancer. Dig. Dis. Sci. 65, 865–873 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Yang, J., Zhou, X., Liu, X., Ling, Z. & Ji, F. Role of the gastric microbiome in gastric cancer: from carcinogenesis to treatment. Front. Microbiol. 12, 641322 (2021).

PubMed  PubMed Central  Google Scholar 

Wu, F. et al. Oral and gastric microbiome in relation to gastric intestinal metaplasia. Int. J. Cancer 150, 928–940 (2022).

CAS  PubMed  Google Scholar 

Ferreira, R. M. et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 67, 226–236 (2018).

CAS  PubMed  Google Scholar 

Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).

PubMed  Google Scholar 

Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20 (2006).

CAS  PubMed  Google Scholar 

Smyth, E. C. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (Suppl. 5), v38–v49 (2016).

CAS  PubMed  Google Scholar 

Thuss-Patience, P. C. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306–2314 (2011).

CAS  PubMed  Google Scholar 

Ford, H. E. R. et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 15, 78–86 (2014).

CAS  PubMed  Google Scholar 

Iizumi, S., Takashima, A., Sakamaki, K., Morita, S. & Boku, N. Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. Cancer Chemother. Pharmacol. 81, 981–989 (2018).

CAS  PubMed  Google Scholar 

Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).

CAS  PubMed  Google Scholar 

Al-Batran, S. E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26, 1435–1442 (2008).

CAS  PubMed  Google Scholar 

Hall, P. S. et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol. 7, 869–877 (2021).

PubMed  PubMed Central